Receives Product Registration and Initial Order for Argentina HALIFAX, April 20 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid diagnostic solutions, announced today that it has received an initial order for MiraWell(R) Rapid HIV Tests (MiraWell HIV) from its agent, EXPORTRADE CORP (EXPORTRADE) of Boca Raton, Florida. The tests will be sold to hospitals, physicians and various government testing programs in Argentina through AC Corp., a member of EXPORTRADE's distribution network. Prior to receiving this order, MedMira and EXPORTRADE worked together to secure official product registration for MiraWell HIV in Argentina, an important first step in opening the market for sale of MedMira products. "We consider product registration and subsequent sales activity in Argentina to be a critical step in developing the Latin American market," said Giles Crouch, vice president of global sales & marketing, MedMira. "Working closely with EXPORTRADE in Argentina, as well as with our other representatives in Latin America to achieve country registrations followed by sales, will allow us to continue growing this market for our rapid HIV tests and future products, including co-infection tests for HIV and Hepatitis C." Most rapid HIV testing is conducted in professional labs in Argentina using serum/plasma. The MiraWell HIV test can be used with serum/plasma as well as whole blood, which will open further markets in rural areas where no suitable lab facilities are readily available. Crouch continued, "Product and technical training with EXPORTRADE's in-country representatives will begin shortly and we look forward to launching MiraWell HIV nationally within the next few months." Rapid HIV tests are a key tool in preventing and controlling the spread of HIV. Some 1.8 million Latin Americans are infected with the HIV-AIDS virus, according to the United Nations, with Brazil, Argentina and Colombia the worst hit. Providing instant test results will help increase the number of people who know their HIV status and subsequently seek appropriate medications and treatment. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow-through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively. MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MiraCare(TM) is sold through MedMira's distributor network to pharmacies, hospitals and laboratories in the European Union. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Guilin, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail: ; Andrea Young, Corporate Communications, Tel. (902) 450-1588, Email:

Copyright